New Leaf Venture Partners
is a leading healthcare technology investor, managing approximately $1
billion in funds, and investments in 49 companies. We focus on 3
sectors: biopharmaceuticals, medical devices, and information
convergence. Our goal is to build strong companies by supporting
exceptional teams in the development of clinically important and
commercially attractive products.
Across all sectors and stages, our investment decisions are primarily
driven by a fundamental assessment of the risks in the underlying
development programs (i.e., technical, clinical, regulatory, and
commercial risks). Before making an investment, we work with the
management teams to identify key milestones that must be met to reach points of meaningful value
inflection, and we ensure that adequate resources are provided for the
company to achieve those milestones.
The NLV investment team has deep operating experience and medical and
technical expertise which are integral to our active investment
approach. This allows us to work closely with founders, management, and
co-investors to identify and execute on a capital efficient and optimal
path to value creation and exit. This focused and fundamentals driven
investment approach generates attractive returns for our investors.
NLV Partners has offices in New York and Menlo Park, California. We are
currently making new investments through New Leaf Ventures II, a $450
million fund, which started its investing cycle in mid-2008.
Relypsa Completes Patient Enrollment in Pivotal Phase 3 Program for the Treatment of Hyperkalemia
Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD
Chimerix Announces Pricing of Initial Public Offering
Durata Therapeutics Closes Public Offering of Common Stock
MEI Pharma’s Mitochondrial Inhibitor Drug Candidate ME-344 Delays Tumor Growth in Recurrent Ovarian Cancer Model